Pulse Biosciences WKN: A2AMY9 ISIN: US74587B1017 Kürzel: PLSE Forum: Aktien User: Solix

👀

⛱️

Company Updates Continued active engagement and collaboration with the nine commercial clinics participating in the CellFX System utilization program. Received FDA 510(k) clearance of expanded energy settings for use with the family of CellFX System treatment tips in dermatology. Generated second quarter 2022 revenue of $265 thousand. Completed two commercial sales of CellFX Systems in the second quarter of 2022. Transitioned four Controlled Launch Program participants to commercial use, totaling 43 commercial conversions with 12 clinics remaining in the Controlled Launch program, after a total of 15 clinics opted out, as of the end of Q2. Reduced Q2 GAAP operating expenses by $3.9 million, or 23%, and Non-GAAP operating expenses by $2.9 million, or 21%, compared to the prior quarter. Completed a rights offering in June, raising $15.0 million in gross proceeds with the potential to raise additional gross proceeds of up to $15.0 million through the exercise of accompanying warrants.

Pulse Biosciences kündigt strategische Änderung des Schwerpunkts zur Unterstützung bedeutender zusätzlicher Möglichkeiten für medizinische Nano-Puls-Stimulation an

Pulse Biosciences kündigt FDA 510(k)-Zulassung für die Behandlung von Sebaceous Hyperplasia an